Prostate cancer

Why we focus on prostate cancer

Prostate cancer is the most common cancer in males in the UK, with around 47,700 new prostate cancer cases in the UK each year. Although about half of prostate cancer patients will die with the cancer rather than of it, prostate cancer is still the second leading cause of male cancer death. It is currently difficult to distinguish between latent and aggressive cancers, and once prostate cancer spreads, it is incurable. Therefore, it is important to identify factors that influence both prostate cancer progression and the therapeutic response, and which could be used to develop biomarkers for tumour behaviour and potential targets for novel therapies.

What we do
  • Establish and maintain a male urogenital cancer tissue bank.
  • Identify critical genes in the development and progression of prostate cancer using a genome-wide analysis approach.
  • Identify biomarkers to predict aggressive prostate cancer.
  • Investigate the mechanism and consequence of genomic alterations in prostate cancer development.
  • Investigate the genetic and environmental factors associated with key genomic alterations in prostate cancer.
  • Develop experimental therapies based on specific genetic changes in cancer cells.
  • Investigate the potential of using gene therapy for prostate cancer treatment, including the application of adenovirus.
  • Investigate anti-tumour efficacy and mechanisms of co-inhibitors of androgen receptor activity in late stage prostate cancer.
  • Run clinical trials of optimised hormone therapy for prostate cancer, and alternative hormone and chemotherapy.
Major Funders
  • Orchid
  • Association for International Cancer Research
  • Cancer Research UK
  • GlaxoSmithKline
  • Medical Research Council
Key Publications